Webinar

#Drug discovery #Surface plasmon resonance #Webinar

Watch now: Discover the world’s first 48-Channel SPR platform

Surface plasmon resonance (SPR) has long been the gold standard for characterising molecular interactions in drug discovery, but throughput limitations have historically constrained its use in early-stage screening campaigns where large numbers of compounds or biologics candidates require rapid triage. The Carterra Vega changes that equation. … Read More

Webinar date:
Supported by Carterra
#News

Antibody discovery concept
#Artificial intelligence (AI) #Biologics #Drug discovery #Therapeutic Antibodies #Webinar

Introducing Benchling Biologics: AI infrastructure for modern drug discovery

Antibody discovery is being reshaped by two forces: an explosion of novel formats and the growing role of AI across the DBTL loop. But most teams are still running antibody programmes on software that hasn’t kept pace with science, leaving data siloed and relationships missing. In this webinar, hosted by… Read More

Webinar date:
Supported by Benching
#News

Antibody discovery concept
#Artificial intelligence (AI) #Biologics #Drug discovery #Therapeutic Antibodies #Webinar

Introducing Benchling Biologics: AI infrastructure for modern drug discovery

Antibody discovery is being reshaped by two forces: an explosion of novel formats and the growing role of AI across the DBTL loop. But most teams are still running antibody programmes on software that hasn’t kept pace with science, leaving data siloed and relationships missing. In this webinar on 11… Read More

Webinar date:
Supported by Benchling
#Webinars

Artificial intelligence
#Artificial intelligence (AI) #Drug discovery #Peptides #Webinar

Cyclic peptide drug design: From experimental discovery to AI-driven computation

Cyclic peptides have a special power in the therapeutic space — they’re larger and more specific than small molecules, and more permeable and cost-effective than antibodies. These qualities enable them to conquer two of the biggest challenges in modern drug development: prosecuting flat intracellular protein-protein interactions (PPIs) and achieving oral… Read More

Webinar date:
Supported by BioDuro
#News

#Drug discovery #Surface plasmon resonance #Webinar

Watch now: Scale your drug discovery programme by 12x

Surface plasmon resonance (SPR) has long been the gold standard for characterising molecular interactions in drug discovery, but throughput limitations have historically constrained its use in early-stage screening campaigns where large numbers of compounds or biologics candidates require rapid triage. The Carterra Vega changes that equation. … Read More

Webinar date:
Supported by Carterra
#News

#Drug discovery #Surface plasmon resonance #Webinar

Scale your drug discovery programme by 12x: Introducing the world’s first 48-Channel SPR platform

Surface plasmon resonance (SPR) has long been the gold standard for characterising molecular interactions in drug discovery, but throughput limitations have historically constrained its use in early-stage screening campaigns where large numbers of compounds or biologics candidates require rapid triage. The Carterra Vega changes that equation.  This… Read More

Webinar date:
Supported by Carterra
#Webinars

Peptides
#Artificial intelligence (AI) #Drug discovery #Peptides #Webinar

Webinar: The art and science of cyclic peptide drug design

Cyclic peptides have a special power in the therapeutic space — they’re larger and more specific than small molecules, and more permeable and cost-effective than antibodies. These qualities enable them to conquer two of the biggest challenges in modern drug development: prosecuting flat intracellular protein-protein interactions (PPIs) and achieving oral… Read More

Webinar date:
Supported by BioDuro
#News

Peptides
#Artificial intelligence (AI) #Drug discovery #Peptides #Webinar

The art and science of cyclic peptide drug design: From experimental discovery to AI-driven computation

Cyclic peptides have a special power in the therapeutic space — they’re larger and more specific than small molecules, and more permeable and cost-effective than antibodies. These qualities enable them to conquer two of the biggest challenges in modern drug development: prosecuting flat intracellular protein-protein interactions (PPIs) and achieving oral… Read More

Webinar date:
Supported by BioDuro
#Webinars

Antibody-drug conjugates
#Antibody drug conjugate (ADC) #Drug discovery #Webinar

Last chance to register: Overcome the challenges of antibody-drug conjugate development

Antibody-drug conjugates (ADCs) hold great promise in targeted therapies, yet their development in the drug discovery phase involves complex challenges in chemistry, biology, and DMPK. This webinar, on 6 May 2026, will demonstrate how integrated strategies help overcome these hurdles and support informed preclinical decisions. Innovative chemistry enables efficient conjugation,… Read More

Webinar date:
Supported by BioDuro
#News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Drug discovery #Webinar

Webinar: Gain insights into ADC biological activity and mechanism-of-action

Antibody-drug conjugates (ADCs) hold great promise in targeted therapies, yet their development in the drug discovery phase involves complex challenges in chemistry, biology, and DMPK. This webinar, on 6 May 2026, will demonstrate how integrated strategies help overcome these hurdles and support informed preclinical decisions. Innovative chemistry enables efficient conjugation,… Read More

Webinar date:
Supported by BioDuro
#News

Antibody-drug conjugate
#Antibody drug conjugate (ADC) #Drug discovery #Webinar

Webinar: Learn how to streamline ADC discovery

Antibody-drug conjugates (ADCs) hold great promise in targeted therapies, yet their development in the drug discovery phase involves complex challenges in chemistry, biology, and DMPK. This webinar, available on-demand, will demonstrate how integrated strategies help overcome these hurdles and support informed preclinical decisions. Innovative chemistry enables efficient conjugation, optimised linkers,… Read More

Webinar date:
Supported by BioDuro
#News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Drug discovery #Webinar

Webinar: Overcome the hurdles in ADC discovery

Antibody-drug conjugates (ADCs) hold great promise in targeted therapies, yet their development in the drug discovery phase involves complex challenges in chemistry, biology, and DMPK. This webinar, available on-demand, will demonstrate how integrated strategies help overcome these hurdles and support informed preclinical decisions. Innovative chemistry enables efficient conjugation, optimised linkers,… Read More

Webinar date:
Supported by BioDuro
#News

Antibody-drug conjugates
#Antibody drug conjugate (ADC) #Drug discovery #Webinar

Webinar: Practical insights on accelerating ADC discovery

Antibody-drug conjugates (ADCs) hold great promise in targeted therapies, yet their development in the drug discovery phase involves complex challenges in chemistry, biology, and DMPK. This webinar, available on-demand, will demonstrate how integrated strategies help overcome these hurdles and support informed preclinical decisions. Innovative chemistry enables efficient conjugation, optimised linkers,… Read More

Webinar date:
Supported by BioDuro
#News

Antibody-drug conjugates
#Antibody drug conjugate (ADC) #Drug discovery #Webinar

Accelerating ADC discovery through strategically integrated chemistry, biology, and DMPK

Antibody-drug conjugates (ADCs) hold great promise in targeted therapies, yet their development in the drug discovery phase involves complex challenges in chemistry, biology, and DMPK. This webinar demonstrates how integrated strategies help overcome these hurdles and support informed preclinical decisions. Innovative chemistry enables efficient conjugation, optimised linkers, and payload selection,… Read More

Webinar date:
Supported by BioDuro
#Webinars

#Antibody drug conjugate (ADC) #LC-MS #Monoclonal antibodies #Oligonucleotides #Webinar

Last chance to register: Understand LC-MS quantification strategies for proteins

A new event, hosted by DDW and supported by Evotec, will explore cutting-edge LC-MS-based bioanalytical approaches tailored for the quantitative analysis of therapeutic proteins, such as monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), fusion protein biomarkers, and oligonucleotides in biological fluids and tissues. The webinar, taking place on 27 March, will… Read More

Webinar date:
Supported by Evotec
#News

#Antibody drug conjugate (ADC) #LC-MS #Monoclonal antibodies #Oligonucleotides #Webinar

Webinar: Learn about LC-MS-based bioanalytical approaches

A new event, hosted by DDW and supported by Evotec, will explore cutting-edge LC-MS-based bioanalytical approaches tailored for the quantitative analysis of therapeutic proteins, such as monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), fusion protein biomarkers, and oligonucleotides in biological fluids and tissues. The webinar, taking place on 27 March, will… Read More

Webinar date:
Supported by Evotec
#News